Cipla Ltd. Launches Shanghai CP Guojian's Biosimilar in India

Published: Apr 19, 2013

by Richard Daverman, PhD

April 18, 2013 -- Cipla Ltd., an Indian generic drug company, has begun marketing a biosimilar version of the rheumatoid arthritis treatment Enbrel, which it sources from Shanghai CP Guojian Pharmaceutical Co. CPGJ has been selling the drug in China since 2006, where it has been given to more than 50,000 patients. Cipla described its relationship with CPGJ as a “partnership.” More details....

Stock Symbol: (BSE: 500087)

Back to news